JP2007505883A5 - - Google Patents

Download PDF

Info

Publication number
JP2007505883A5
JP2007505883A5 JP2006526715A JP2006526715A JP2007505883A5 JP 2007505883 A5 JP2007505883 A5 JP 2007505883A5 JP 2006526715 A JP2006526715 A JP 2006526715A JP 2006526715 A JP2006526715 A JP 2006526715A JP 2007505883 A5 JP2007505883 A5 JP 2007505883A5
Authority
JP
Japan
Prior art keywords
parathyroid hormone
composition
osteoporosis
treating
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007505883A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/002902 external-priority patent/WO2005027915A1/en
Publication of JP2007505883A publication Critical patent/JP2007505883A/ja
Publication of JP2007505883A5 publication Critical patent/JP2007505883A5/ja
Pending legal-status Critical Current

Links

JP2006526715A 2003-09-19 2004-09-06 2−アルキリデン−19−ノル−ビタミンd誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法 Pending JP2007505883A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50450303P 2003-09-19 2003-09-19
PCT/IB2004/002902 WO2005027915A1 (en) 2003-09-19 2004-09-06 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone

Publications (2)

Publication Number Publication Date
JP2007505883A JP2007505883A (ja) 2007-03-15
JP2007505883A5 true JP2007505883A5 (enExample) 2007-11-08

Family

ID=34375509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526715A Pending JP2007505883A (ja) 2003-09-19 2004-09-06 2−アルキリデン−19−ノル−ビタミンd誘導体及び副甲状腺ホルモンの組合せを含んでなる医薬組成物及び方法

Country Status (15)

Country Link
US (1) US20050065088A1 (enExample)
EP (1) EP1667689A1 (enExample)
JP (1) JP2007505883A (enExample)
KR (1) KR20060058133A (enExample)
CN (1) CN1852716A (enExample)
AU (1) AU2004273660B2 (enExample)
BR (1) BRPI0414518A (enExample)
CA (1) CA2539357A1 (enExample)
IL (1) IL174144A0 (enExample)
MX (1) MXPA06003064A (enExample)
NO (1) NO20061236L (enExample)
NZ (1) NZ545803A (enExample)
RU (1) RU2006108557A (enExample)
TW (1) TW200511999A (enExample)
WO (1) WO2005027915A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
WO2005051323A2 (en) * 2003-11-25 2005-06-09 Wisconsin Alumni Research Foundation Vitamin d analogs for obesity prevention and treatment
WO2005051396A2 (en) * 2003-11-25 2005-06-09 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
CA2597624C (en) * 2005-02-11 2012-08-14 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20s-24s)-1.alpha.,25-dihydroxyvitamin-d2
US7511030B2 (en) * 2005-02-11 2009-03-31 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20S-24epi)-1α,25-dihydroxyvitamin D2
WO2006105221A1 (en) * 2005-03-29 2006-10-05 Wisconsin Alumni Research Foundation 2-METHYLENE-19-NOR-(23S)-25-DEHYDRO-1α-HYDROXYVITAMIN D3-26,23-LACTONE AND 2-METHYLENE-19-NOR-(23R)-25-DEHYDRO-1α-HYDROXYVITAMIN D3-26,23-LACTONE
US20110237557A1 (en) * 2010-03-23 2011-09-29 Deluca Hector F Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
US8604009B2 (en) 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
WO2015050160A1 (ja) * 2013-10-03 2015-04-09 国立大学法人大阪大学 副甲状腺ホルモンまたはその誘導体を有効成分とする筋の老化防止用医薬組成物
WO2015064585A1 (ja) * 2013-10-29 2015-05-07 国立大学法人熊本大学 筋疾患の治療または予防のための医薬組成物
KR20200053069A (ko) * 2018-11-07 2020-05-18 주식회사 노브메타파마 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78342A (en) * 1985-04-04 1991-06-10 Gen Hospital Corp Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
JP2898882B2 (ja) * 1993-04-05 1999-06-02 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 2−位に置換基を有する19−ノル−ビタミンd3 化合物
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
EP1295605A3 (en) * 1998-08-19 2003-10-29 Eli Lilly And Company Method of increasing bone toughness and stiffness and reducing fractures
AR033639A1 (es) * 1998-08-19 2004-01-07 Lilly Co Eli Uso de hormonas paratiroideas para preparar medicamentos para reducir el riesgo de fracturas oseas vertebrales o no vertebrales en seres humanos con riesgo de padecer o que padecen osteoporosis

Similar Documents

Publication Publication Date Title
JP2007505883A5 (enExample)
JP2006143751A5 (enExample)
WO2005115441A3 (en) Compositions and methods for enhanced mucosal delivery of parathyroid hormone
DE50311502D1 (de) Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung
DE602004013971D1 (de) Marknagel zur Behandlung von proximalen Oberschenkelknochenbrüchen
JP2017036323A5 (enExample)
ATE491436T1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
IL219915A0 (en) Pharmaceutical composition for the treatment or prevention of diseases involving obesity, diabetes, metabolic syndrome, neuro-degenerative diseases and mitochondria dysfunction diseases
ATE390407T1 (de) Phenethanolamin-derivate zur behandlung von atemwegserkrankungen
IL158593A (en) Arylsulfonamide compounds, process for preparation thereof and pharmaceutical compositions for the treatment of obesity, type ii diabetes and cns-disorders
EP2168962A3 (en) Phenylacetamides and their use as glucokinase modulators
CY1116665T1 (el) Χρηση παραγωγων του ινδολοξικου οξεος που αυξανουν το επιπεδο ορου του παραγοντα igf-1 για την παρασκευη μιας θεραπευτικης συνθεσης για τη θεραπεια διαφορων νοσων
JP2018508530A5 (enExample)
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
JP2011519960A5 (enExample)
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
JP2008512426A5 (enExample)
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
JP2008513510A5 (enExample)
DE602004029465D1 (de) Externes Präparat zur Behandlung von Fusspilz
ECSP044961A (es) Acido n-(5-clorosaliciloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides
JP2005509503A5 (enExample)
RU2006108557A (ru) Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения)
DE60218375D1 (de) Pharmazeutische Zusammensetzung zur Behandlung gynäkologischer Erkrankungen